357 filings
8-K
IMGN
Immunogen, Inc.
12 Feb 24
Termination of a Material Definitive Agreement
7:52am
8-K
IMGN
Immunogen, Inc.
8 Feb 24
Other Events
7:08am
8-K
IMGN
Immunogen, Inc.
31 Jan 24
Submission of Matters to a Vote of Security Holders
4:12pm
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
8-K
w4iolqbdai0x8 a95
8 Jan 24
Other Events
4:11pm
8-K
b1cvak3 xnnqtd
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
oeq6n2hi03njb1
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
ryk 3l2qf
18 Sep 23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
6:35am
8-K
l8xw4ae5ohvq 6e2uqx
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
uyum4zax7b4a
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
kxi 536t0
5 May 23
Entry into a Material Definitive Agreement
5:15pm
8-K
7r7ow0s
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
xgibt hgp215
2 May 23
Entry into a Material Definitive Agreement
5:01pm
8-K
tasqj1t
28 Apr 23
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
6:36am
8-K
b79hqyjy
6 Apr 23
ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
6:35am
8-K
vjwb1mkv
1 Mar 23
ImmunoGen Reports Recent Progress and 2022 Financial Results
6:40am
8-K
y5ljgcqg0swl7xkwfz
1 Mar 23
Entry into a Material Definitive Agreement
6:38am
8-K
j30kgz0p804nvrjn3
9 Jan 23
Results of Operations and Financial Condition
6:40am
8-K
kjl01vt4qh66addzi qr
4 Jan 23
ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs
6:38am